Tesamorelin + CJC-1295 (No DAC) + Ipamorelin Blend is supplied as one laboratory research vial containing Tesamorelin 6mg, CJC-1295 without DAC (Mod GRF 1-29) 3mg and Ipamorelin 3mg, for 12mg combined nominal content. The CJC component is the supplier-confirmed no-DAC form, also named Mod GRF 1-29; no prolonged DAC half-life is claimed. The component amounts describe the listed material rather than a human dose or prepared solution concentration. The illustrated 3ml marking refers to container capacity.
The 12mg total combines two GHRH-related components with Ipamorelin in a 6:3:3 mass ratio. Combining related compounds does not establish complementary action, increased selectivity or improved clinical outcomes. This page distinguishes the named ingredients and the research questions they raise from results for the finished mixture.
Tesamorelin trials measured visceral adiposity in HIV-associated settings. Ipamorelin research studied secretagogue activity separately; the triple blend was not tested. The references below explain the specific study context. No direct study of this exact supplied blend was identified in this review. Comparisons should distinguish individual-component evidence from mixture-specific stability, interactions and biological activity; a source link is not an endorsement or batch certification.
Match the product designation, individual component identities and stated amounts against the relevant analytical report before drawing laboratory conclusions. The SRP research chart is explanatory, and the COA, chromatography, mass-spectrometry and traceability illustrations are educational examples, not test results for this vial. For laboratory research only; not for human or veterinary use, diagnosis or treatment.
Reviews
There are no reviews yet.